Hear from the scientists switching to Optimer® synthetic binders for new breakthroughs where antibodies have failed. Traditional antibodies often fall short when precision and reliability matter most. In this…
Optimer® radiopharmaceutical programme initiated with Radiopharmium Ltd Three therapeutic targets selected across high‑value clinical indications Pipeline planned for four radiotherapy assets with in vivo data expected by end…
Aptamer stability can be tuned for clearance mechanism and to prevent nuclease activity. As the number of aptamers in the clinical pipeline grows, it demonstrates that aptamer stability can…
The stability of aptamers impacts performance in therapeutics and diagnostic assays. One of the key benefits of using aptamers instead of antibodies is how you store and use your…
Optimer can act as non-viral vectors and precisely target specific tissue and cell types to deliver conjugated RNA therapies right into the cell. As RNA therapies continue to increase in…
Site-specific delivery remains a significant challenge faced by novel RNA therapies. The use of cell or tissue targeting Optimer non-viral vectors can help to overcome the three major…
Liver fibrosis determines long-term morbidity and mortality in liver disease. We explore the biology behind liver fibrosis and the need for new precision treatments in this space. What is liver…
Optimer offers significant advantages to enhance the antibody-drug conjugate (ADC) toolkit for improved precision medicines.
Cancer remains a mammoth challenge, accounting for one in every six deaths globally. But aptamers are offering new solutions from reagents to next-gen ADCs. Despite the scale of the…
In this webinar Aptamer’s Chief Scientific Officer, Dr David Bunka, discusses how Optimers can be used for developing cancer research reagents, new therapies and diagnostic tools. Aptamers, initially discovered…
